Fig. 3
From: Serum butyrylcholinesterase activity as a predictor of severity and mortality in COVID-19 patients
Serum BChE activity in patients with various symptoms. (A) Respiratory symptoms: No significant differences in BChE levels were observed with cough (P = 0.1089, n = 179, A1), pulmonary failure P = 0.5811, n = 18, A4), or odynophagia (P = 0.5113, n = 23, D3), but levels were significantly lower in patients with pneumonia (P = 0.0027, n = 50, A2) and dyspnea (P = 0.0120, n = 120, A3) compared to patients without these symptoms (n = 283, n = 444, n = 412, n = 317, n = 439 respectively). (B) Gastrointestinal symptoms: No significant differences were seen in patients with vomitus (P = 0.5775, n = 24, B1), diarrhea (P = 0.2773, n = 52, B2), or anorexia (P = 0.5341, n = 13, B3) compared to those without these symptoms (n = 438, n = 410, and n = 449, respectively). (C) Neurological symptoms: BChE activity was significantly higher in patients with anosmia (P < 0.0001, n = 44, C1), ageusia (P = 0.0012, n = 40, C2), or headache (P = 0.0005, n = 73, C3) compared to those without these symptoms (n = 418, n = 422, n = 389, respectively). (D) Musculoskeletal symptoms: No significant difference in BChE activity were observed in patients with myalgia (P = 0.6085, n = 45, D1), or arthralgia (P = 0.7449, n = 30, D2) compared to those without these symptoms (n = 417, n = 432, respectively). (E) Systemic symptoms: No significant difference in BChE activity were found in patients with fever (P = 0.0571, n = 187, E1) or chills (P = 0.9169, n = 11, E2) compared to those without these symptoms (n = 275, n = 451, respectively). BChE Butyrylcholinesterase.
